Ed Marx

Ed Marx

Nashville, Tennessee, United States
1K followers 500+ connections

About

Experienced analytics professional with a demonstrated history of building and leading…

Activity

Join now to see all activity

Experience

  • Vanderbilt University Medical Center Graphic
  • -

    Greater Nashville Area, TN

  • -

  • -

  • -

  • -

    Greater Nashville Area, TN

  • -

    Greater Philadelphia Area

  • -

    Greater Pittsburgh Area

  • -

    Greater Pittsburgh Area

  • -

    Mehoopany, PA

  • -

    Mehoopany, PA

Education

  • Harvard Business School Graphic
  • -

    Activities and Societies: University Scholars Program (now Schreyer Honors College); President AIChE; THON

Publications

  • Optimizing Personalized Bone Marrow Testing Using an Evidence-Based, Interdisciplinary Team Approach

    American Journal of Clinical Pathology

    Objectives: To address the overuse of testing that complicates patient care, diminishes quality, and increases costs by implementing the diagnostic management team, a multidisciplinary system for the development and deployment of diagnostic testing guidelines for hematologic malignancies. Methods: The team created evidence-based standard ordering protocols (SOPs) for cytogenetic and molecular testing that were applied by pathologists to bone marrow biopsy specimens on adult patients. Testing on…

    Objectives: To address the overuse of testing that complicates patient care, diminishes quality, and increases costs by implementing the diagnostic management team, a multidisciplinary system for the development and deployment of diagnostic testing guidelines for hematologic malignancies. Methods: The team created evidence-based standard ordering protocols (SOPs) for cytogenetic and molecular testing that were applied by pathologists to bone marrow biopsy specimens on adult patients. Testing on 780 biopsy specimens performed during the six months before SOP implementation was compared with 1,806 biopsy specimens performed during the subsequent 12 months. Results: After implementation, there were significant decreases in tests discordant with SOPs, omitted tests, and the estimated cost of testing to payers. The fraction of positive tests increased. Clinicians reported acceptance of the new procedures and perceived time savings. Conclusions: This process is a model for optimizing complex and personalized diagnostic testing.

    Other authors
    • Adam C. Seegmiller, MD, PhD
    • Annette S. Kim, MD, PhD
    • Claudio A. Mosse, MD, PhD
    • Mia A. Levy, MD, PhD
    • Mary Ann Thompson Arildsen, MD, PhD
    • Madan H. Jagasia, MD
    • Robert S. Dittus, MD
    • William W. Stead, MD
    • Samuel  A. Santoro, MD, PhD
    • Mary Zutter, MD
  • Limited Utility of Fluorescence in Situ Hybridization for Common Abnormalities of Myelodysplastic Syndrome at First Presentation and Follow-up of Myeloid Neoplasms

    Leukemia & Lymphoma

    Fluorescence in situ hybridization for abnormalities common to myelodysplastic syndrome (MDS FISH) is often used with traditional karyotype in the diagnosis and monitoring of myeloid neoplasms. However, its value in these roles has been questioned. To evaluate its utility, we compared MDS FISH results with karyotype in 544 bone marrow specimens obtained for diagnosis (180 cases) or follow-up (364 cases) of myeloid neoplasia. We found excellent concordance between FISH and karyotype, such that…

    Fluorescence in situ hybridization for abnormalities common to myelodysplastic syndrome (MDS FISH) is often used with traditional karyotype in the diagnosis and monitoring of myeloid neoplasms. However, its value in these roles has been questioned. To evaluate its utility, we compared MDS FISH results with karyotype in 544 bone marrow specimens obtained for diagnosis (180 cases) or follow-up (364 cases) of myeloid neoplasia. We found excellent concordance between FISH and karyotype, such that FISH is rarely abnormal (1.7% at diagnosis and 3.0% at follow-up) in cases with normal karyotype. Even in the rare discordant cases, the abnormal FISH has little or no clinical value. Thus, we propose that this test should be limited to cases with inadequate karyotype only. Such guidelines could result in significant cost savings with no impact on patient diagnosis.

    Other authors
    • Adam C. Seegmiller, MD, PhD
    • Allison Wasserman, MD
    • Annette S. Kim, MD, PhD
    • Megan K. Kressin, MD
    • Mary M. Zutter, MD
    • Claudio A. Mosse, MD, PhD
    See publication
  • Confluence of Policy and Leadership in Academic Health Science Centers

    Radcliffe Publishing

    Co-authored chapter: Contemporary Challenges in Academic Health Science Center Financial Management

    Other authors
    • Jeffrey R. Balser, MD, PhD
    • John F. Manning, PhD

Organizations

  • Penn State Schreyer Honors College

    External Advisory Board

    - Present
  • Penn State Schreyer Honors College

    Scholar Alumni Society Board

    - Present

Recommendations received

More activity by Ed

View Ed’s full profile

  • See who you know in common
  • Get introduced
  • Contact Ed directly
Join to view full profile

Other similar profiles

Explore collaborative articles

We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.

Explore More

Others named Ed Marx in United States

Add new skills with these courses